MAFFICINI, Andrea
MAFFICINI, Andrea
DIPARTIMENTO DI INGEGNERIA PER LA MEDICINA DI INNOVAZIONE
Characterization of new monoclonal antibodies specific for the extracellular domain of PTPRG, a candidate tumour suppressor gene
2010-01-01 Vezzalini, Marzia; Mafficini, Andrea; Moratti, Elisabetta; Sorio, Claudio
Development of FT-IR microspectroscopy for pre-clinical and clinical applications
2008-01-01 Bellisola, Giuseppe; Bergamini, Corinna; BOLOMINI VITTORI, Matteo; Cestelli Guidi, M.; Cinque, G.; DELLA PERUTA, Marco; Giagulli, Cinzia; Laudanna, Carlo; Mafficini, Andrea; Marcelli, A.; Melotti, Paola Maria; Piccinini, M.; Sorio, Claudio
Down-regulation of protein tyrosine phosphatase gamma (PTPRG) in chronic myeloid leukemia (CML)
2008-01-01 DELLA PERUTA, Marco; Giovanni, Martinelli; Maria, Monne; Pintani, Davide; Tiziana, Grafone; Ilaria, Iacobucci; Marco, Murineddu; Vinante, Fabrizio; Tecchio, Cristina; Vezzalini, Marzia; Giovanna, Piras; Attilio, Gabbas; Mafficini, Andrea; Sorio, Claudio
IMPACT OF POLYMORPHIC-794 CATT REPEATS OF MACROPHAGE MIGRATION INHIBITORY FACTOR PROMOTER ON SEVERITY OF CF
2012-01-01 Mafficini, A; Teresinha, L; Lebecque, P; Ortombina, M; Sorio, Claudio; Pintani, E; Pepermans, X; Assael, Baroukhmaurice; Melotti, Paola Maria
Impact of the polymorphic variant 5 FR/G-260C in the Multidrug Resistance-associate Protein-1 gene on severity of cystic fibrosis
2009-01-01 Mafficini, Andrea; M., Ortombina; I., Sermet Gaudelus; P., Lebecque; T., Leal; A., Leonard; G., Reychler; K., Dahan; X., Papermans; G., Lenoir; Sorio, Claudio; P., Iansa; B. M., Assael; Melotti, Paola Maria
Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers
2019-01-01 Simbolo, M; Mafficini, A; Vicentini, C; Ruzzenente, A; Rusev, B; Brunelli, M; Pedron, S; Bertuzzo, F; Barbi, S; Fassan, M; Corbo, V; Bagante, F; Turri, G; Luchini, C; Lawlor, R; Guglielmi, A; Bassi, C; Scarpa, A
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models
2018-01-01 Gkountakos, A; Pilotto, S; Simbolo, M; Vicentini, C; Mafficini, A; Del Curatolo, A; Scarpa, A; Tortora, G; Corbo, V; Bria, E
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations
2018-01-01 Pilotto, S; Grizzi, G; Sperduti, I; Simbolo, M; Vicentini, C; Caliò, A; Caccese, M; Mafficini, A; Carbognin, L; Corbo, V; Gkountakos, A; Santo, A; Infante, M; Brunelli, M; Scarpa, A; Tortora, G; Bria, E
PTPRG Expression Correlates with Tolerogenic Phenotype in Dendritic Cells Derived from Pancreatic Cancer Patients
2006-01-01 Mafficini, Andrea; Bellone, G.; Bonora, Antonio; Crippa, Stefano; Vezzalini, Marzia; DELLA PERUTA, Marco; Scarpa, Aldo; Sorio, Claudio
Receptor type tyrosine phosphatase gamma (PTP gamma) is a novel dendritic cell marker
2004-01-01 Lissandrini, D; Vermi, W; Vezzalini, M; Sozzani, S; Facchetti, F; Mafficini, A; Sorio, Claudio
UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A NEW USEFUL MARKER IN PANCREATIC CANCER: PRELIMINARY RESULTS
2007-01-01 Antonio, Bonora; Sorio, Claudio; Federico, Furlan; Maraia, Gianluigi; Mafficini, Andrea; Crippa, Stefano; DELLA PERUTA, Marco; Bassi, Claudio; Pederzoli, Paolo; Cavallini, Alvise
Urokinase Plasminogen Activator Receptor Could Be a New UsefulMarker in Pancreatic Cancer and Appears to Be Related to Survival
2007-01-01 Bonora, Antonio; Sorio, Claudio; Furlan, F.; Maraia, Gianluigi; Mafficini, Andrea; Pederzoli, Paolo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Characterization of new monoclonal antibodies specific for the extracellular domain of PTPRG, a candidate tumour suppressor gene | 1-gen-2010 | Vezzalini, Marzia; Mafficini, Andrea; Moratti, Elisabetta; Sorio, Claudio | |
| Development of FT-IR microspectroscopy for pre-clinical and clinical applications | 1-gen-2008 | Bellisola, Giuseppe; Bergamini, Corinna; BOLOMINI VITTORI, Matteo; Cestelli Guidi, M.; Cinque, G.; DELLA PERUTA, Marco; Giagulli, Cinzia; Laudanna, Carlo; Mafficini, Andrea; Marcelli, A.; Melotti, Paola Maria; Piccinini, M.; Sorio, Claudio | |
| Down-regulation of protein tyrosine phosphatase gamma (PTPRG) in chronic myeloid leukemia (CML) | 1-gen-2008 | DELLA PERUTA, Marco; Giovanni, Martinelli; Maria, Monne; Pintani, Davide; Tiziana, Grafone; Ilaria, Iacobucci; Marco, Murineddu; Vinante, Fabrizio; Tecchio, Cristina; Vezzalini, Marzia; Giovanna, Piras; Attilio, Gabbas; Mafficini, Andrea; Sorio, Claudio | |
| IMPACT OF POLYMORPHIC-794 CATT REPEATS OF MACROPHAGE MIGRATION INHIBITORY FACTOR PROMOTER ON SEVERITY OF CF | 1-gen-2012 | Mafficini, A; Teresinha, L; Lebecque, P; Ortombina, M; Sorio, Claudio; Pintani, E; Pepermans, X; Assael, Baroukhmaurice; Melotti, Paola Maria | |
| Impact of the polymorphic variant 5 FR/G-260C in the Multidrug Resistance-associate Protein-1 gene on severity of cystic fibrosis | 1-gen-2009 | Mafficini, Andrea; M., Ortombina; I., Sermet Gaudelus; P., Lebecque; T., Leal; A., Leonard; G., Reychler; K., Dahan; X., Papermans; G., Lenoir; Sorio, Claudio; P., Iansa; B. M., Assael; Melotti, Paola Maria | |
| Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers | 1-gen-2019 | Simbolo, M; Mafficini, A; Vicentini, C; Ruzzenente, A; Rusev, B; Brunelli, M; Pedron, S; Bertuzzo, F; Barbi, S; Fassan, M; Corbo, V; Bagante, F; Turri, G; Luchini, C; Lawlor, R; Guglielmi, A; Bassi, C; Scarpa, A | |
| Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models | 1-gen-2018 | Gkountakos, A; Pilotto, S; Simbolo, M; Vicentini, C; Mafficini, A; Del Curatolo, A; Scarpa, A; Tortora, G; Corbo, V; Bria, E | |
| Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations | 1-gen-2018 | Pilotto, S; Grizzi, G; Sperduti, I; Simbolo, M; Vicentini, C; Caliò, A; Caccese, M; Mafficini, A; Carbognin, L; Corbo, V; Gkountakos, A; Santo, A; Infante, M; Brunelli, M; Scarpa, A; Tortora, G; Bria, E | |
| PTPRG Expression Correlates with Tolerogenic Phenotype in Dendritic Cells Derived from Pancreatic Cancer Patients | 1-gen-2006 | Mafficini, Andrea; Bellone, G.; Bonora, Antonio; Crippa, Stefano; Vezzalini, Marzia; DELLA PERUTA, Marco; Scarpa, Aldo; Sorio, Claudio | |
| Receptor type tyrosine phosphatase gamma (PTP gamma) is a novel dendritic cell marker | 1-gen-2004 | Lissandrini, D; Vermi, W; Vezzalini, M; Sozzani, S; Facchetti, F; Mafficini, A; Sorio, Claudio | |
| UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A NEW USEFUL MARKER IN PANCREATIC CANCER: PRELIMINARY RESULTS | 1-gen-2007 | Antonio, Bonora; Sorio, Claudio; Federico, Furlan; Maraia, Gianluigi; Mafficini, Andrea; Crippa, Stefano; DELLA PERUTA, Marco; Bassi, Claudio; Pederzoli, Paolo; Cavallini, Alvise | |
| Urokinase Plasminogen Activator Receptor Could Be a New UsefulMarker in Pancreatic Cancer and Appears to Be Related to Survival | 1-gen-2007 | Bonora, Antonio; Sorio, Claudio; Furlan, F.; Maraia, Gianluigi; Mafficini, Andrea; Pederzoli, Paolo |